In association with the
By repairing or replacing dysfunctional cells, tissues and organs, regenerative therapies promise to treat injuries and diseases like cancer, Alzheimer's, Parkinson's, diabetes and cardiovascular disorders that are incurable today. In particular, cellular therapies have proved highly effective in treating patients with blood cancer. Furthermore, recent clinical studies indicate that these therapies may also be effective against solid tumors.
The highly complex manufacturing of cell-based therapies nevertheless remains problematic despite their clinical success. The alliance aims to automate the manufacturing process of cell-based therapies using recent technology developments in cell culturing, analytical instrumentation and artificial intelligence.
Cell therapies are today meticulously cultured and manufactured by hand in an open laboratory environment, making it difficult to scale up manufacturing -- much like the automotive industry before the invention of the assembly line.
BioSpherix has been building Cytocentric cell culture equipment since 1983. It will provide a sealed, sterile and cell-friendly environment to the alliance where cells are cultured at controlled temperature, oxygen and CO2 levels without human contact.
SAS will provide the AI expertise and software infrastructure to automatically analyze the wealth of data collected by the
The 6 100-employee strong
Equally important, PHI will provide non-invasive single-cell imaging data quantifying cellular behavior and morphology without using compromising reagents.
The Wake Forest Ecosystem of Regenerative Medicine
This new alliance stems from these companies associated with the RegeneratOR, a key component of the regenerative medicine ecosystem in
This disclosure contains information that
For additional information, please contact:
E-mail: ir@phiab.se
Web: www.phiab.com - Live cell imaging & analysis
https://news.cision.com/phase-holographic/r/phi--sas--qiagen-and-biospherix-form-alliance-to-advance-cell-based-biomanufacturing,c3666351
https://mb.cision.com/Main/11597/3666351/1667767.pdf
https://news.cision.com/phase-holographic/i/cell-therapy-quality-inspection-lonza,c3113602
(c) 2022 Cision. All rights reserved., source